InfiltrateID™ Quantification of the Immunocellular Content in the Tumor Microenvironment The emergence and success of immuno-oncology drugs in the treatment of several cancer types has transformed clinical practice. However, many patients do not respond to these drugs, compelling researchers and clinicians to broaden their search for biomarkers that can better [...]
NeXT Liquid Biopsy™ It’s Time to Think About More. High-Performance Whole Exome Sequencing from Plasma. Complementing Tumor Tissue Profiling with Plasma-based Global Resolution NeXT Liquid Biopsy™, a high-performance, exome-wide liquid biopsy assay, is designed to complement Personalis’ flagship tissue-based immunogenomics platform, ImmunoID NeXT™, to further enhance the development of [...]
NeXT Dx™ Test Gene List Cancer Genes of Clinical Importance Single nucleotide variants, small insertions and deletions, copy number alterations, and gene fusions involving the genes in the NeXT Dx Test Gene List may be reported in the test. Genes in BOLD are those for which FDA approved drugs are [...]
SHERPA™ Bioinformatics Engine Systematic HLA Epitope Ranking Technologies for neoantigen discovery are critical for developing personalized cancer vaccines and neoantigen-based biomarkers. Precision neoantigen discovery entails the comprehensive detection of tumor-specific genomic variants and accurate prediction of MHC presentation of epitopes originating from such variants. Personalis’ ImmunoID NeXT™ enables a comprehensive survey [...]
NeXT Liquid Biopsy™ It’s Time to Think About More. High-Performance Whole Exome Sequencing from Plasma. Highlights Comprehensively profile the tumor, exome-wide Combined with ImmunoID NeXT™, assess tumor heterogeneity, monitor response to therapy, and interrogate mechanisms of resistance Profile with ImmunoID NeXT, Monitor with NeXT Liquid Biopsy Leverage somatic variant [...]
